Division of Clinical Pharmacy, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, California, United States of America.
Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville, Florida, United States of America.
PLoS One. 2023 Feb 2;18(2):e0281068. doi: 10.1371/journal.pone.0281068. eCollection 2023.
Atrial fibrillation (AF) is associated with a five-fold increased risk of stroke and a two-fold increased risk of death. We aimed to quantify changes in new diagnoses of AF following the onset of the COVID-19 pandemic. Investigating changes in new diagnoses of AF is of relevance because delayed diagnosis interferes with timely treatment to prevent stroke, heart failure, and death.
Using De-identified Optum's Clinformatics® Data Mart, we identified 19,500,401 beneficiaries continuously enrolled for 12 months in 2016-Q3 2020 with no history of AF. The primary outcome was new AF diagnoses per 30-day interval. Secondary outcomes included AF diagnosis in the inpatient setting, AF diagnosis in the outpatient setting, and ischemic stroke as initial manifestation of AF. We constructed seasonal autoregressive integrated moving average models to quantify changes in new AF diagnoses after the onset of the COVID-19 pandemic (3/11/2020, date of pandemic declaration). We tested whether changes in the new AF diagnoses differed by race and ethnicity.
The average age of study participants was 51.0±18.5 years, and 52% of the sample was female. During the study period, 2.7% of the study sample had newly-diagnosed AF. New AF diagnoses decreased by 35% (95% CI, 21%-48%) after the onset of the COVID-19 pandemic, from 1.14 per 1000 individuals (95% CI, 1.05-1.24) to 0.74 per 1000 (95% CI, 0.64 to 0.83, p-value<0.001). New AF diagnoses decreased by 37% (95% CI, 13%- 55%) in the outpatient setting and by 29% (95% CI, 14%-43%) in the inpatient setting. The decrease in new AF diagnoses was similar across racial and ethnic subgroups.
In a nationwide cohort of 19.5 million individuals, new diagnoses of AF decreased substantially following the onset of the COVID-19 pandemic. Our findings evidence pandemic disruptions in access to care for AF, which are concerning because delayed diagnosis interferes with timely treatment to prevent complications.
心房颤动(AF)与中风风险增加五倍和死亡风险增加两倍相关。我们旨在量化 COVID-19 大流行开始后新诊断的 AF 变化。研究新诊断的 AF 变化很重要,因为延迟诊断会干扰及时治疗以预防中风、心力衰竭和死亡。
使用 De-identified Optum 的 Clinformatics® Data Mart,我们在 2016 年第三季度至 2020 年期间确定了 19500401 名连续 12 个月没有 AF 病史的受益人的数据。主要结局是每 30 天间隔新的 AF 诊断。次要结局包括住院患者中的 AF 诊断、门诊患者中的 AF 诊断以及 AF 作为初始表现的缺血性中风。我们构建了季节性自回归综合移动平均模型,以量化 COVID-19 大流行开始后(2020 年 3 月 11 日,大流行宣布日期)新的 AF 诊断变化。我们测试了新的 AF 诊断变化是否因种族和民族而异。
研究参与者的平均年龄为 51.0±18.5 岁,样本中有 52%为女性。在研究期间,研究样本中有 2.7%的人被新诊断为 AF。COVID-19 大流行开始后,新的 AF 诊断减少了 35%(95%CI,21%-48%),从每 1000 人 1.14 例(95%CI,1.05-1.24)降至每 1000 人 0.74 例(95%CI,0.64-0.83,p 值<0.001)。门诊环境中的新 AF 诊断减少了 37%(95%CI,13%-55%),住院环境中的新 AF 诊断减少了 29%(95%CI,14%-43%)。新的 AF 诊断减少在不同种族和民族亚组中相似。
在一项全国性的 1950 万人队列中,COVID-19 大流行开始后,新诊断的 AF 明显减少。我们的研究结果表明,大流行期间 AF 治疗的机会减少,这令人担忧,因为延迟诊断会干扰及时治疗以预防并发症。